Publications by the researcher in collaboration with Miguel Unda Urzaiz (14)

2023

  1. A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer

    Actas Urologicas Espanolas, Vol. 47, Núm. 2, pp. 111-126

  2. Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors’ reply

    Actas Urologicas Espanolas

  3. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial

    European urology oncology, Vol. 6, Núm. 1, pp. 58-66

2022

  1. Non-metastatic castration-resistant prostate cancer: management recommendations

    Actas Urologicas Espanolas, Vol. 46, Núm. 4, pp. 193-213

2018

  1. Safety and efficacy of various strains of bacille Calmette-Guérin in the treatment of bladder tumours in standard clinical practice

    Actas Urologicas Espanolas, Vol. 42, Núm. 4, pp. 238-248

2017

  1. Consenso sobre el manejo del cáncer de próstata resistente a la castración avanzado en España

    Archivos Espanoles de Urologia, Vol. 70, Núm. 9, pp. 777-791

  2. Diagnosis and treatment for clinically localized prostate cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study – GESCAP group

    Actas Urologicas Espanolas, Vol. 41, Núm. 6, pp. 359-367

2016

  1. Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer

    Critical Reviews in Oncology/Hematology, Vol. 100, pp. 127-136

  2. Tendencias de tratamiento en el cáncer de próstata clínicamente localizado. Análisis poblacional a nivel nacional: grupo GESCAP

    Actas Urologicas Espanolas, Vol. 40, Núm. 4, pp. 209-216

2014

  1. Bladder cancer in Spain 2011: Population based study

    Journal of Urology, Vol. 191, Núm. 2, pp. 323-328

  2. Factors that predict the development of bone metastases due to prostate cancer: Recommendations for follow-up and therapeutic options

    Actas Urologicas Espanolas

2013

  1. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

    British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572

2011

  1. Prostate cancer in Spain: From guidelines to clinical practice

    BJU International, Vol. 108, Núm. 1, pp. 61-66

2005

  1. Cáncer de próstata de alto riesgo y diseminado (Documento de Consenso de Recomendaciones)

    Actas Urologicas Espanolas, Vol. 29, Núm. 9, pp. 826-827